Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.
J Clin Oncol. 2016 Feb 22. pii: JCO651463. [Epub ahead of print]
Nyame YA1, Murphy AB2, Bowen DK1, Jordan G1, Batai K1, Dixon M1, Hollowell CM1, Kielb S1, Meeks JJ1, Gann PH1, Macias V1, Kajdacsy-Balla A1, Catalona WJ1, Kittles R1.
1Yaw A. Nyame, Cleveland Clinic, Cleveland, Ohio; Adam B. Murphy, Diana K. Bowen, Gregory Jordan, Michael Dixon, Stephanie Kielb, Joshua J. Meeks, and William J. Catalona, Northwestern University, Chicago; Courtney M.P. Hollowell, Cook County Health and Hospitals System; Peter H. Gann, Virgilia Macias, and Andre Kajdacsy-Balla, University of Illinois at Chicago, Chicago, IL; and Ken Batai and Rick Kittles, University of Arizona, Tucson, AZ.
2Yaw A. Nyame, Cleveland Clinic, Cleveland, Ohio; Adam B. Murphy, Diana K. Bowen, Gregory Jordan, Michael Dixon, Stephanie Kielb, Joshua J. Meeks, and William J. Catalona, Northwestern University, Chicago; Courtney M.P. Hollowell, Cook County Health and Hospitals System; Peter H. Gann, Virgilia Macias, and Andre Kajdacsy-Balla, University of Illinois at Chicago, Chicago, IL; and Ken Batai and Rick Kittles, University of Arizona, Tucson, AZ. a-murphy2 at northwestern.edu.
PURPOSE:
Lower serum vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels.
METHODS:
This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy.
RESULTS:
Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. The median age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) compared with their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01).
CONCLUSION:
Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.
© 2016 by American Society of Clinical Oncology.
PMID: 26903577
See also VitaminDWiki
- 16 percent less Prostate Cancer sometimes for each 10 ng vitamin D increase - meta-analysis Jan 2011
- Overview Prostate Cancer and Vitamin D
- Prostate cancer reduced when 4000 IU vitamin D was added– Hollis RCT April 2015
- If parents exposed to pesticides, genes changed. will need more vitamin D to avoid Prostate Cancer – July 2013
- Can take 40,000 IU of vitamin D daily before prostate cancer surgery – RCT March 2013